Literature DB >> 12669471

Anti-interferon-gamma antibodies in the treatment of autoimmune diseases.

Boris Skurkovich1, Simon Skurkovich.   

Abstract

Interferon (IFN)-gamma is an important immune regulator in normal immunity. When IFN gamma production is disturbed, various autoimmune diseases (ADs) can develop, in which we suggest that anti-IFN gamma could have a beneficial effect. Depending on the cell type in which IFN gamma synthesis is disturbed, different clinical manifestations may result. We have also proposed to remove tumor necrosis factor (TNF)-alpha, together with certain types of IFNs, to treat various ADs and AIDS, also an autoimmune condition. Anti-IFN gamma has been tested in several T-helper cell (Th1) ADs, including rheumatoid arthritis (RA), multiple sclerosis (MS), corneal transplant rejection, uveitis, Type I diabetes, schizophrenia (anti-IFN gamma and anti-TNF alpha), and various autoimmune skin diseases (alopecia areata, psoriasis vulgaris, vitiligo, pemphigus vulgaris and epidermolysis bullosa). A strong, sometimes striking, therapeutic response followed administration of anti-IFN gamma, indicating that it may be a promising therapy for Th1 ADs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669471

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  13 in total

1.  AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells.

Authors:  So Jin Bing; Itay Shemesh; Wai Po Chong; Reiko Horai; Yingyos Jittayasothorn; Phyllis B Silver; Benjamin Sredni; Rachel R Caspi
Journal:  J Autoimmun       Date:  2019-03-08       Impact factor: 7.094

2.  Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice.

Authors:  R Ito; M Shin-Ya; T Kishida; A Urano; R Takada; J Sakagami; J Imanishi; M Kita; Y Ueda; Y Iwakura; K Kataoka; T Okanoue; O Mazda
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

3.  Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses.

Authors:  Sonali Joshi; Leonidas C Platanias
Journal:  Biomol Concepts       Date:  2012-04

4.  Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.

Authors:  Manuela B Pucca; Thaís B Bertolini; Felipe A Cerni; Karla C F Bordon; Steve Peigneur; Jan Tytgat; Vânia L Bonato; Eliane C Arantes
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

Review 5.  The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature.

Authors:  R L Rabin; A I Levinson
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

Review 6.  Clinical Use of Interferon-gamma.

Authors:  Catriona H T Miller; Stephen G Maher; Howard A Young
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

Review 7.  Autoimmunity as a double agent in tumor killing and cancer promotion.

Authors:  Kevin H Toomer; Zhibin Chen
Journal:  Front Immunol       Date:  2014-03-18       Impact factor: 7.561

8.  A key role of the mitochondrial citrate carrier (SLC25A1) in TNFα- and IFNγ-triggered inflammation.

Authors:  Maria Laura Avantaggiati; Ferdinando Palmieri; Vittoria Infantino; Vito Iacobazzi; Alessio Menga
Journal:  Biochim Biophys Acta       Date:  2014-07-27

9.  IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts.

Authors:  Martin Rottman; Claire Soudais; Guillaume Vogt; Laurent Renia; Jean-François Emile; Hélène Decaluwe; Jean-Louis Gaillard; Jean-Laurent Casanova
Journal:  PLoS Med       Date:  2008-01-29       Impact factor: 11.069

Review 10.  A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods.

Authors:  Marialaura Madrigal; Kosagisharaf S Rao; Neil H Riordan
Journal:  J Transl Med       Date:  2014-10-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.